慢性複雑性尿路感染症に対するAB-206の使用経験 (AB-206(MILOXACIN:MLX))
スポンサーリンク
概要
- 論文の詳細を見る
Clinical and bacteriological studies on AB-206 in the field of urology were carried out and the following results were obtained.<BR>1) Clinical results<BR>AB-206 was administered to 16 cases with chronic complicated U. T. I. at dosage of 1g/day for 7 days. Effectiveness was shown excellent in 5, good in 2, poor in 8 and unknown in 1 case (drop-out because of side effect). Efficacy ratio was 46.7% totally.<BR>2) Bacteriological effects<BR>Bacteriological effectiveness of AB-206 was shown eradicated in 4, decreased in 3, unchanged in 8 and unknown in 1 strain. Efficacy ratio was 46.7% totally.<BR>3) Antibacterial activities<BR>MICs were measured in 10 clinical isolated organisms and AB-206 was susceptible to most of all that included NA-and PA-resistant strains. Clinical efficacy was also observed in some of those patients.<BR>4) Side effects<BR>Out of 16 cases, side effect was noted in only 1 case with upper abdominal discomfort. No other side effects and abnormalities of laboratory findings were noted.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.